PTPI — Petros Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Petros Pharmaceuticals’ STENDRA Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance
Brief: Petros Pharmaceuticals Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Petros Pharmaceuticals Expands Online Distribution For Prescription STENDRA(R) Through New Agreement With Lemonaid Health
Brief: Petros Pharma Announces Partnership with Idea Evolver for Rx-to-OTC Switches & Digital Launch Solutions
Brief: Petros Pharmaceuticals Announces Capital Raise Of $15 Million
U.S. STOCKS ON THE MOVE-Boeing, Lucid, Nikola
Advisory: (OFFICIAL)-Alerts on Petros Pharma deal withdrawn as company clarifies
Brief: Petros Pharmaceuticals Says Confirmed A Press Release Issued On July 28, 2022 Regarding Purported Acquisition Of Co Was Fraudulent And Not Issued By Co
Brief: Petros Pharmaceuticals Reports Q1 2022 Results
Brief: Petros Pharmaceuticals To Pursue 505(B)(2) Pathway For H-100, Company’S Novel Topical Investigational Treatment For Peyronie’S Disease Which Impacts More Than 1 In 10 Men In The Us
Brief: Petros Pharma Engages Massachusetts General Hospital In Sponsored Research Agreement For Tissue-Specific Oxygenation Sensor Technology
Petros jumps on positive OTC label study data for erectile dysfunction drug
Brief: Petros Announces Results Of OTC Label Comprehension Study For Erectile Dysfunction Drug Stendra
Brief: Petros Pharmaceuticals Partners With Leading Global Contract Manufacturer
Brief: Petros Pharmaceuticals Says Unit Entered Into A Technology Transfer Service Agreement With Patheon Pharmaceuticals
Brief: Petros Pharmaceuticals Says On Jan 18 Metuchen Pharmaceuticals Llc, A Unit Of Co And Vivus Llc Entered Into A Settlement Agreement
Brief: Petros Pharmaceuticals Launches Two Self-Selection Studies For Erectile Dysfunction Drug Stendra® (Avanafil)
Brief: Petros Pharmaceuticals Announces $7.5 Million Offering
NASDAQ RESUMED AT 10:09 AM